Senaparib

Senaparib
Clinical data
Trade names	Paishuning
Other names	IMP-4297
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	L01XK07 (WHO) ;
Legal status
Legal status	CN: Rx-only;
Identifiers
	IUPAC name 5-fluoro-1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione;
CAS Number	1401682-78-7;
PubChem CID	68389008;
DrugBank	DB17163;
ChemSpider	103704755;
UNII	MNZ4OP95CF;
KEGG	D13232;
ChEMBL	ChEMBL4802152;
Chemical and physical data
Formula	C24H20F2N6O3
Molar mass	478.460 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCN1C2=NC=CC=N2)C(=O)C3=C(C=CC(=C3)CN4C5=C(C(=CC=C5)F)C(=O)NC4=O)F;
	InChI InChI=1S/C24H20F2N6O3/c25-17-6-5-15(14-32-19-4-1-3-18(26)20(19)21(33)29-24(32)35)13-16(17)22(34)30-9-11-31(12-10-30)23-27-7-2-8-28-23/h1-8,13H,9-12,14H2,(H,29,33,35); Key:VBTUJTGLLREMNW-UHFFFAOYSA-N;

Senaparib, sold under the brand name Paishuning, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is a PARP inhibitor.

In January 2025, senaparib was approved for use in China for treatment of advanced epithelial high-grade ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Medical uses

Senaparib is indicated as monotherapy for the maintenance treatment of adults with advanced (FIGO Stages III and IV) epithelial high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

Society and culture

Legal status

Senaparib was approved for medical use in China in January 2025.

In September 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Sepalna, intended for the maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer. The applicant for this medicinal product is SFL Pharmaceuticals Deutschland.

Names

Senaparib is the international nonproprietary name.

Senaparib is sold under the brand name Paishuning.

References

↑ Lee A (November 2025). "Senaparib: First Approval". Drugs. 85 (11): 1473–1477. doi:10.1007/s40265-025-02200-1. PMID 40736646.
↑ Lee A (November 2025). "Correction: Senaparib: First Approval". Drugs. 85 (11): 1507–1508. doi:10.1007/s40265-025-02245-2. PMID 41091366.
1 2 3 4 "Sepalna EPAR". European Medicines Agency (EMA). 18 September 2026. Retrieved 17 October 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ "Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer". onclive.com. 17 January 2025.
1 2 "Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer" (Press release). Impact Therapeutics. 16 January 2025. Retrieved 17 October 2026 – via PR Newswire.
↑ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.

External links

"Senaparib ( Code - C168601 )". EVS Explore. Retrieved 17 October 2026.
"Senaparib Hydrochloride ( Code - C222180 )". EVS Explore. Retrieved 17 October 2026.
Clinical trial number NCT04169997 for "A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer (FLAMES)" at ClinicalTrials.gov

[1] Lee A (November 2025). "Senaparib: First Approval". Drugs. 85 (11): 1473–1477. doi:10.1007/s40265-025-02200-1. PMID 40736646.

[2] Lee A (November 2025). "Correction: Senaparib: First Approval". Drugs. 85 (11): 1507–1508. doi:10.1007/s40265-025-02245-2. PMID 41091366.

[Sepalna_EPAR-3] 1 2 3 4 "Sepalna EPAR". European Medicines Agency (EMA). 18 September 2026. Retrieved 17 October 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[4] "Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer". onclive.com. 17 January 2025.

[Impact_PR-5] 1 2 "Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer" (Press release). Impact Therapeutics. 16 January 2025. Retrieved 17 October 2026 – via PR Newswire.

[6] World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.